Clinical Development and Market Access Strategy: Why They Must Align
Biotech and pharmaceutical companies often treat clinical development and market access as sequential, separate workstreams: first prove the drug works and gets approved, then figure out how to get it paid for. In practice, this sequencing creates avoidable risk.
Trial designs finalized without payer and health technology assessment (HTA) requirements in mind frequently produce clinical data that satisfies regulators but falls short of what payers need to justify coverage.
Understanding both clinical development solutions and market access strategy consulting — and how they relate — is increasingly essential for companies trying to avoid a costly gap between regulatory approval and commercial success.
What Clinical Development Solutions Cover
Clinical development solutions span the operational and scientific work required to move a therapy from first-in-human studies through regulatory submission. Depending on a sponsor’s internal capabilities, this can include:
- Trial design and protocol development, including endpoint selection, comparator arms, and statistical planning.
- Site selection, patient recruitment, and monitoring, often the most time- and cost-intensive part of a trial.
- Regulatory strategy and submissions, coordinating with FDA (and other regulators for multi-region trials) on study design and data requirements.
- Data management, biostatistics, and medical writing, converting trial results into submission-ready documentation.
- Functional service provider (FSP) or full-service CRO models, depending on how much a sponsor wants to outsource versus retain in-house.
Smaller biotechs with limited internal infrastructure typically rely more heavily on full-service CRO partnerships, while larger, established pharma companies often use a hybrid model — building core capabilities internally and outsourcing selectively for specialized needs or capacity.
What Market Access Strategy Consulting Covers
Market access work focuses on what happens after — or increasingly, alongside — clinical development: ensuring a therapy is actually accessible to the patients it’s approved for. This includes:
- Payer and HTA engagement strategy, understanding what evidence and value story a given payer or health authority requires for coverage.
- Pricing and reimbursement strategy, including health economics and outcomes research (HEOR) to support value-based pricing discussions.
- Patient access program design, such as copay assistance or prior authorization navigation support.
- Value proposition and dossier development, translating clinical and real-world data into materials payers and formulary committees can act on.
Read: Pharmaceutical Software Solutions and Development
Where the Two Intersect — and Why That Matters
The connection between these two functions comes down to evidence. A trial designed purely to satisfy regulatory approval standards may use a comparator, endpoint, or patient population that regulators accept but payers find insufficient to justify premium pricing or preferred formulary placement.
Industry discussion around integrated evidence generation planning increasingly emphasizes bringing market access and HEOR input into protocol design early — before patient enrollment begins — so that the same trial, or a parallel real-world evidence study, generates data useful for both regulatory and payer audiences simultaneously.
This doesn’t mean every company needs market access input dictating every clinical decision. It means treating “what will payers need to see” as a design input alongside “what will regulators require,” rather than discovering the gap after a pivotal trial has already locked its protocol.
Practical Considerations for Evaluating Partners
For clinical development partners, evaluate:
- Relevant therapeutic area experience, particularly for complex or novel modalities.
- Track record on trial timelines and patient recruitment in comparable indications.
- Whether services are offered as full-service CRO engagement or more flexible functional service provider models, matching your internal capability gaps.
For market access consulting partners, evaluate:
- Depth of payer and HTA relationships specific to your product’s therapeutic area and target markets.
- Whether their HEOR and real-world evidence capabilities can integrate with, rather than duplicate, your clinical development data.
- Experience with your specific access challenge — novel pricing models, rare disease reimbursement, or biosimilar competition each require different expertise.
For companies evaluating whether to integrate the two functions, a useful early question is whether your current clinical development partner and market access consultant (if different organizations) have a structured process for sharing input on trial design, or whether that coordination is left informal and ad hoc.
Conclusion
Clinical development and market access strategy consulting are distinct disciplines with different skill sets, but treating them as entirely separate workstreams increases the risk of approved therapies that struggle commercially.
Companies planning a development program should build in a structured checkpoint — ideally before pivotal trial design is finalized — where market access considerations inform endpoint, comparator, and evidence generation decisions.
Whether that coordination happens through an integrated partner or deliberate collaboration between separate clinical development and market access consulting teams, the goal is the same: avoid discovering a payer evidence gap after it’s too late to fix.